Aytu BioPharma (NASDAQ:AYTU) Releases Quarterly Earnings, Misses Estimates by $0.37 EPS

Aytu BioPharma (NASDAQ:AYTU – Get Your Free Report ) released its quarterly earnings data on Thursday. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.37), Zacks reports. Aytu BioPharma had a negative return on equity of 31.31% and a negative net margin of 14.60%.

Aytu BioPharma trading up 17.2%

NASDAQ:AYTU opened at $2.85 on Friday. The company has a 50-day moving average of $2.53 and a 200-day moving average of $2.83. Aytu BioPharma has a 12-month low of $1.66 and a 12-month high of $3.50. The firm has a market cap of $17.01 million, a price-to-earnings ratio of -1.08 and a beta of -1.43.

Aytu BioPharma company profile

(Get a free report)

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, is focused on commercializing novel therapeutics and consumer health care products in the United States and internationally. The company operates through two segments: the Rx segment and the Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients six years of age and older and Cotempla XR-ODT for patients six to seventeen years of age.

Recommended articles

Get news and reviews for Aytu BioPharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aytu BioPharma and related companies with MarketBeat.com ‘s FREE daily email newsletter.